E
Adverum Biotechnologies, Inc. ADVM
$2.97 $0.124.21% NASDAQ
Recommendation
Prev Close
$2.85
Volume
639,061
Avg Vol (90D)
194,566
Market Cap
$59.54M
Dividend & Yield
--
52-Week Range
$2.72 - $11.21
P/E (TTM)
--
EPS (TTM)
-$6.59
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and More
4/24/2025 - Insider Monkey
Video: Thursday 4/24 Insider Buying Report: ADVM, ALLY
4/24/2025 - Market News Video
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
4/22/2025 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
4/21/2025 - Globe Newswire
Truist Financial Initiates a Buy Rating on Adverum Biotechnologies (ADVM)
4/21/2025 - TipRanks Financial Blog
Chardan Capital Has Lowered Expectations for Adverum Biotechnologies (NASDAQ:ADVM) Stock Price
4/19/2025 - MarketBeat
Royal Bank of Canada Lowers Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $5.00
4/18/2025 - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Rating of "Moderate Buy" from Analysts
4/18/2025 - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Given Buy Rating at HC Wainwright
4/18/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
4/17/2025 - Globe Newswire
Adverum Biotechnologies (NASDAQ:ADVM) Releases Earnings Results
4/17/2025 - MarketBeat
HC Wainwright Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM)
4/16/2025 - Ticker Report
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
4/16/2025 - TipRanks Financial Blog
ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. ...
4/15/2025 - GuruFocus
Adverum Biotechnologies (NASDAQ:ADVM) Announces Earnings Results
4/15/2025 - Ticker Report
Adverum Biotechnologies Inc Reports Q4 2024 EPS of -$1.96, Missing Estimates; No Revenue Reported
4/15/2025 - GuruFocus
ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm
4/15/2025 - PR Newswire
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and ...
4/15/2025 - GuruFocus
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and ...
4/15/2025 - GuruFocus
Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
4/15/2025 - TipRanks Financial Blog
Adverum Biotechnologies GAAP EPS of -$1.96 misses by $0.60
4/15/2025 - SeekingAlpha.com: All News
Adverum Biotechnologies sees cash runway into 2H25
4/15/2025 - TipRanks Financial Blog
Adverum Biotechnologies announces anticipated milestones
4/15/2025 - TipRanks Financial Blog
Adverum Biotechnologies announces anticipated milestones
4/15/2025 - The Fly
Adverum Biotechnologies sees cash runway into 2H25
4/15/2025 - The Fly
Income Statement
Total Revenue (TTM)
$1.00M
EBITDA (TTM)
-$135.51M
EBIT (TTM)
-$139.16M
Net Income (TTM)
-$130.93M
Balance Sheet
Total Assets (Q)
$179.84M
Total Debt (Q)
$91.71M
Total Liabilities (Q)
$109.13M
Book Value Per Share (Q)
$3.39
Cash Flow
Cash from Operations (TTM)
-$92.46M
Cash from Investing (TTM)
-$41.89M
Cash from Financing (TTM)
$120.00M
Net Change in Cash (TTM)
-$14.35M
Filings
Filing Date
Tuesday, April 15, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
1.08
7-Day Total Return
-13.41%
30-Day Total Return
-38.64%
60-Day Total Return
-32.96%
90-Day Total Return
-49.92%
Year to Date Total Return
-38.13%
1-Year Total Return
-70.85%
2-Year Total Return
-67.07%
3-Year Total Return
-75.04%
5-Year Total Return
-97.71%
52-week Low
Apr 21, 2025 - $2.72
52-week High
Apr 24, 2024 - $11.21
Valuation
Market Cap
$59.54M - Micro Cap
Enterprise Value
$25.55M
Price/Sales (TTM)
59.62
Price/Book (Q)
0.84
Dividends and Shares
Shares Outstanding
20.90M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
adverum.com
Phone Number
650 656 9323
Address
100 Cardinal Way
Redwood City, CA 94063
Country
United States
Year Founded
2006
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a... more
NASDAQ 04/24/2025 4:00PM Eastern Quotes delayed